126.03
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$126.92
Offen:
$127.2
24-Stunden-Volumen:
447.55K
Relative Volume:
0.27
Marktkapitalisierung:
$19.85B
Einnahmen:
$9.82B
Nettoeinkommen (Verlust:
$1.48B
KGV:
12.44
EPS:
10.13
Netto-Cashflow:
$2.30B
1W Leistung:
-0.79%
1M Leistung:
-1.83%
6M Leistung:
-16.70%
1J Leistung:
-44.89%
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
BIIB
Biogen Inc
|
126.06 | 19.85B | 9.82B | 1.48B | 2.30B | 10.13 |
![]()
LLY
Lilly Eli Co
|
777.28 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
152.22 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
![]()
NVO
Novo Nordisk Adr
|
68.34 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
![]()
ABBV
Abbvie Inc
|
184.41 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
![]()
NVS
Novartis Ag Adr
|
119.94 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
2025-04-04 | Herabstufung | Argus | Buy → Hold |
2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2024-12-16 | Herabstufung | Stifel | Buy → Hold |
2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
2024-11-18 | Herabstufung | Needham | Buy → Hold |
2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
2024-11-14 | Eingeleitet | Citigroup | Neutral |
2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
2024-02-14 | Bestätigt | Needham | Buy |
2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2024-01-24 | Herabstufung | UBS | Buy → Neutral |
2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2023-09-06 | Eingeleitet | HSBC Securities | Buy |
2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
2023-07-24 | Bestätigt | UBS | Buy |
2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
2022-10-13 | Hochstufung | Stifel | Hold → Buy |
2022-10-07 | Hochstufung | Argus | Hold → Buy |
2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2022-03-08 | Herabstufung | Stifel | Buy → Hold |
2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2022-02-04 | Bestätigt | Barclays | Equal Weight |
2022-02-04 | Bestätigt | BofA Securities | Neutral |
2022-02-04 | Bestätigt | Cowen | Outperform |
2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
2022-02-04 | Bestätigt | Needham | Buy |
2022-02-04 | Bestätigt | Oppenheimer | Outperform |
2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
2022-02-04 | Bestätigt | Wedbush | Neutral |
2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
2021-12-06 | Eingeleitet | Goldman | Neutral |
2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
2021-09-23 | Eingeleitet | Needham | Buy |
2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
2021-06-14 | Bestätigt | Truist | Buy |
2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
2021-06-10 | Hochstufung | UBS | Neutral → Buy |
2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
2021-06-08 | Bestätigt | Barclays | Equal Weight |
2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
2021-06-08 | Bestätigt | Jefferies | Buy |
2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
2021-06-08 | Bestätigt | Stifel | Buy |
2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
2021-01-29 | Hochstufung | Stifel | Hold → Buy |
2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2020-10-28 | Eingeleitet | UBS | Neutral |
2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
2020-02-27 | Eingeleitet | Barclays | Overweight |
2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Missouri Trust & Investment Co Has $866,000 Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Not Over Yet: Eisai And Lilly To Appeal England’s ‘Flawed’ Refusal To Fund Leqembi And Kisunla - insights.citeline.com
Grimes & Company Inc. Purchases 33,721 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Fifth Third Bancorp Has $751,000 Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen bids to extend use of Skyclarys to younger patients - pharmaphorum
Biogen Dips on Its Part in BRAVE Study - Baystreet.ca
H.C. Wainwright sees potential competition for Sage from Biogen - Yahoo Finance
Biogen (BIIB) Launches Global Phase 3 BRAVE Study for Omaveloxol - GuruFocus
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia | BIIB Stock News - GuruFocus
Biogen initiates phase 3 trial of omaveloxolone for children with FA - Investing.com
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia - Biogen
How the Neuroprotection Therapeutics Market Will Evolve by 2032 - openPR.com
Harbor Capital Advisors Inc. Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Targets Rare Diseases, Eyes $800M Cost Cuts With ‘Fit for Growth’ Plan - MSN
Biogen (NASDAQ:BIIB) Seems To Use Debt Quite Sensibly - simplywall.st
Cutaneous Lupus Erythematosus Market Research Report 2025-2035, Competitive Analysis of Biogen, Bristol-Myers Squibb, Sanofi, AstraZeneca, Gilead Sciences, and Kyowa KirinResearchAndMarkets.com - Bluefield Daily Telegraph
Biogen patents new HTT splicing modulators - BioWorld MedTech
Biogen (BIIB) Considers Bid Amid Sage Therapeutics Merger Developments | BIIB Stock News - GuruFocus
Biogen (BIIB) Involved in Sage Pharmaceuticals Acquisition Deal | BIIB Stock News - GuruFocus
Biogen (BIIB) Eyes Contingent Value in Sage Deal | BIIB Stock News - GuruFocus
Bill Nye joins fireside chat supporting Biogen’s Cannes Lion-winning work - Medical Marketing and Media
NorthCrest Asset Manangement LLC Grows Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Supernus makes depression drug play with $795m Sage buyout - Pharmaceutical Technology
Supernus strikes deal to buy Sage Therapeutics - The Business Journals
After rebuffing Biogen, Sage pairs off with Supernus - pharmaphorum
Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus - BioSpace
After brushing off Biogen, Mass. biotech firm finds buyer for $795M - NBC Boston
Maryland firm outbids Biogen for Sage Therapeutics - The Business Journals
Supernus enters depression drug market with up to $795 million Sage deal - MarketScreener
Biogen (BIIB) Gains from Supernus-Sage Therapeutics Acquisition | BIIB Stock News - GuruFocus
Supernus Pharmaceuticals To Acquire Sage Therapeutics - citybiz
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio - GlobeNewswire
Biogen, UCB Present Positive Phase 3 Results for Lupus Drug Candidate at EULAR 2025 - Insider Monkey
Biogen's (BIIB) "Neutral" Rating Reaffirmed at Piper Sandler - MarketBeat
Pallas Capital Advisors LLC Purchases 7,694 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
From Kentucky farm to founding Biogen: New documentary traces life of Phil Sharp - The Business Journals
Neuroregeneration Therapy Market Know the Scope and Trends | - openPR.com
Data at EULAR back Biogen, UCB's first-in-class lupus drug - pharmaphorum
Biogen Requests to Dismiss Class Action Filed by Investors - TradingView
Biogen (BIIB) Rating and Price Target Reiterated by Piper Sandle - GuruFocus
Biogen (BIIB) Rating and Price Target Reiterated by Piper Sandler Analyst | BIIB Stock News - GuruFocus
Biogen, UCB Take A Leap In Lupus With Promising Phase 3 ResultsBiogen (NASDAQ:BIIB) - Benzinga
Biogen (NASDAQ:BIIB) Earns Neutral Rating from Wedbush - MarketBeat
Biogen (BIIB) Receives Neutral Rating With Price Target Maintained | BIIB Stock News - GuruFocus
Biogen: positive Phase 3 data in lupus - marketscreener.com
Biogen (NASDAQ:BIIB) Receives Hold Rating from Needham & Company LLC - MarketBeat
Demystifying Biogen: Insights From 11 Analyst Reviews - Benzinga
Global Tardive Dyskinesia Treatment Market 2025 | - openPR.com
Biogen (BIIB) Shares Promising Phase 3 Study Results for Lupus D - GuruFocus
Biogen (BIIB) Rating Reiterated as Hold by Needham Analyst | BIIB Stock News - GuruFocus
Biogen (BIIB) Shares Promising Phase 3 Study Results for Lupus Drug Candidate | BIIB Stock News - GuruFocus
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):